人软骨糖蛋白-39在原发性肝癌中的表达以及对TACE术后患者预后的评估价值  

Expression of YKL-40 in hepatocellular carcinoma patients and its value of prognosis evaluation for postoperative patients under TACE

作　　者：徐亚卿[1] 闫胜利[1] 肖峰[1] 

机构地区：[1]安徽省蚌埠市第二人民医院介入科,233000

出　　处：《淮海医药》2015年第3期242-244,共3页Journal of Huaihai Medicine

摘　　要：目的分析人软骨糖蛋白39(YKL-40)在原发性肝癌(HCC)中的表达以及对TACE术后患者预后的评估价值。方法采用酶联免疫吸附法检测87例初诊原发性肝癌患者和25例健康志愿者血清YKL-40水平,同时对54例行肝动脉化疗栓塞(TACE)术患者随访,并于术后1月复测YKL-40水平。结果初诊HCC患者YKL-40平均水平为(331.4±126.8)pg/ml,高于健康人群(184.0±83.7)pg/ml,差异具有统计学意义(P<0.05)。YKL-40水平升高与肿瘤大小有关(P<0.05),与性别、年龄、有无癌栓、AFP水平无关(P>0.05)。TACE术后YKL-40平均水平较术前有所降低,但仍高于健康人群(P<0.05);其中术后YKL-40≥331.4 pg/ml组总体生存时间短于术后YKL-40<331.4 pg/ml组(P<0.05);COX风险回归分析显示术后YKL-40≥331.4 pg/ml是影响HCC患者TACE术后预后的独立危险因素。结论 YKL-40在HCC患者中高表达,动态监测YKL-40可以用于了解TACE术后患者疾病转归,评估预后。Objective To analyze the expression of human cartilage glycoprotein 39（ YKL-40） in hepatocellular carcinoma（ HCC） patients and the value of prognosis evaluation for postoperative patients under transhepatic artery chemotherapy embolism（ TACE）. Methods ELISA was applied to detect serum YKL-40 levels in 87 cases of first diagnosed HCC patients and 25 cases of healthy volunteers. 54 patients who had undergone TACE operation were followed up,and their YKL-40 levels were retested after one month. Results The average value of YKL-40 in HCC patients was 331. 4 ± 126. 8 pg / ml,obviously higher than that of healthy people（ 184. 0 ± 83. 7 pg / ml）. The elevated YKL-40 was associated with tumor size（ P〈0. 05）,and irrelevant to gender,age,tumor embolus and AFP levels（ P〉 0. 05）. The YKL-40 value decreased after TACE operation,but was still higher than that of healthy people（ P〈0. 05）. The overall survival time of postoperative patients with YKL-40≥331. 4 pg /ml was significantly shorter than those with YKL-40 331. 4 pg / ml group（ P〈0. 05）. COX regression analysis showed that postoperative YKL-40≥331. 4 pg / ml was an independent risk factor influencing the prognosis of HCC patients after TACE operation. Conclusion YKL-40 expresses highly in HCC patients. Dynamically monitoring YKL-40 can be employed to judge the disease outcome and evaluate the prognosis of postoperative patients under TACE.

关 键 词：肝肿瘤 化学栓塞 治疗性 人软骨糖蛋白-39 预后 

分 类 号：R735.7[医药卫生—肿瘤]